Switzerland: Sumitovant Bio completes Myovant acquisition

Myovant Sciences Logo

New York-headquartered Sumitovant Biopharma, a wholly owned subsidiary of Sumitomo Pharma, has completed the acquisition of Myovant Sciences, a company on a mission to combine science, medicine, and advocacy to improve the lives of people suffering from uterine fibroids, endometriosis, prostate cancer, or infertility. The acquisition was first announced in October, 2022. Sumitovant has acquired all outstanding…

You must be a HMI Subscriber to view this content.

Subscribe Now »